Genmab A/S (NASDAQ:GMAB) Shares Sold by Venturi Wealth Management LLC

Venturi Wealth Management LLC cut its position in Genmab A/S (NASDAQ:GMAB) by 21.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,889 shares of the company’s stock after selling 5,009 shares during the period. Venturi Wealth Management LLC’s holdings in Genmab A/S were worth $394,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of GMAB. Legacy Wealth Asset Management LLC boosted its holdings in shares of Genmab A/S by 1.1% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock valued at $1,097,000 after buying an additional 471 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after acquiring an additional 827 shares in the last quarter. GAMMA Investing LLC lifted its position in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. Eagle Asset Management Inc. boosted its stake in Genmab A/S by 10.0% in the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after acquiring an additional 1,121 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after purchasing an additional 1,413 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Trading Up 2.1 %

NASDAQ:GMAB opened at $22.44 on Friday. The stock’s 50 day simple moving average is $20.68 and its 200-day simple moving average is $22.97. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88. The firm has a market cap of $14.85 billion, a P/E ratio of 12.90, a PEG ratio of 2.57 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GMAB. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.